SANN.SW - Santhera Pharmaceuticals Holding AG

Swiss - Swiss Delayed Price. Currency in CHF
12.20
-0.20 (-1.61%)
At close: 5:19PM CET
Stock chart is not supported by your current browser
Previous Close12.40
Open12.30
Bid12.20 x 0
Ask12.22 x 0
Day's Range12.12 - 12.30
52 Week Range5.55 - 22.30
Volume6,561
Avg. Volume18,722
Market Cap135.558M
Beta (3Y Monthly)0.78
PE Ratio (TTM)N/A
EPS (TTM)-5.89
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
  • GlobeNewswire

    Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophy

    Pratteln, Switzerland, November 19, 2019 – Santhera Pharmaceuticals (SIX: SANN) announces publication of the previously reported SYROS study data in prominent peer-reviewed.

  • GlobeNewswire

    Santhera Appoints New Chief Executive Officer

    Pratteln, Switzerland, November 4, 2019 – Santhera Pharmaceuticals (SANN.SW) announces a strategic change to its management team with the appointment of Dario Eklund as CEO, effective December 1, 2019. Thomas Meier will continue as a Board Member and will chair the newly formed Board of Director’s Scientific Committee. Thomas Meier, PhD, Chief Executive Officer of Santhera, said: “This is a very exciting time for Santhera.

  • GlobeNewswire

    Vamorolone Designated Promising Innovative Medicine (PIM) for Treatment of Duchenne Muscular Dystrophy by the UK MHRA

    Pratteln, Switzerland, October 21, 2019 – Santhera Pharmaceuticals (SIX: SANN) announces that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has informed.

  • GlobeNewswire

    Santhera Announces Presentation by ReveraGen of Positive 18-Month Data with Vamorolone in Duchenne Muscular Dystrophy

    Pratteln, Switzerland, October 7, 2019 – Santhera Pharmaceuticals (SIX: SANN) announces presentation of data showing continued improvement of muscle function and improved.

  • GlobeNewswire

    Santhera to Present Long-Term Data with Puldysa® (Idebenone) in Duchenne Muscular Dystrophy at Upcoming Medical Congresses

    Pratteln, Switzerland, September 17, 2019 – Santhera Pharmaceuticals (SIX: SANN) will present data on the therapeutic effects of long-term treatment with Puldysa® (idebenone) in.

  • GlobeNewswire

    Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis

    Pratteln, Switzerland, September 10, 2019 – Santhera Pharmaceuticals (SANN.SW) announces the online publication of Phase I data with its human neutrophil elastase (hNE) inhibitor POL6014 in the Journal of Cystic Fibrosis [1]. POL6014 is an innovative, potent and selective inhibitor of human neutrophil elastase (hNE) in clinical development for the treatment of cystic fibrosis (CF). In CF, excessive release of enzymes like hNE accelerates lung tissue inflammation and damage, leading to an incapacitating and progressive decline in pulmonary function.

  • GlobeNewswire

    Santhera Announces Financial Results for the First Half-Year 2019

    A conference call will be held today at 13:00 CEST, 12:00 BST, 07:00 EDT. Details are at the end of this statement. Pratteln, Switzerland, September 3, 2019 – Santhera.

  • GlobeNewswire

    Santhera Announces Publication by ReveraGen of Positive Phase IIa-Extension Study Results with Vamorolone in Patients with Duchenne Muscular Dystrophy

    Pratteln, Switzerland, August 27, 2019 – Santhera Pharmaceuticals (SIX: SANN) announces publication by ReveraGen of positive study data with vamorolone in patients with Duchenne.

  • GlobeNewswire

    Santhera Announces Executive Management Change

    Pratteln, Switzerland, August 9, 2019 – Santhera Pharmaceuticals (SIX: SANN) announces that Christoph Rentsch has decided to step down as Chief Financial Officer of Santhera by end of this year, in order to pursue his career outside the Company. A search for a succession has been initiated and Christoph Rentsch will continue to support the company during the transition period. Elmar Schnee, Chairman of Santhera, said: “Christoph has been a key member of the Executive Management Team over the past four years and has been instrumental in successfully delivering concepts and resources for the strategic diversification of the Company’s pipeline during that period.

  • GlobeNewswire

    Santhera Announces Closing of Licensing Transaction with Chiesi Group for Raxone® in LHON

    Pratteln, Switzerland, August 2, 2019 – Santhera Pharmaceuticals (SANN.SW) announces the closing of the licensing transaction with Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group). As per the agreement, Chiesi Group has in-licensed Raxone® for the treatment of Leber’s hereditary optic neuropathy (LHON) and the initial payment of EUR 44 million of the total consideration of up to EUR 93 million became due.

  • GlobeNewswire

    Santhera's Shareholders Approve all Board Proposals at Today's Annual General Meeting

    Pratteln, Switzerland, May 28, 2019 - Santhera Pharmaceuticals (SANN.SW) announces that a large majority of shareholders approved all proposals by the Board of Directors at the Annual General Meeting (AGM) held today. Participating shareholders represented a total of 4`109`097 shares or 36.8% of the share capital. "I am very pleased about the consent of Santhera`s shareholders at today`s AGM," said Elmar Schnee, Chairman of the Board of Directors.

  • GlobeNewswire

    Santhera Submits Marketing Authorization Application to the European Medicines Agency for Puldysa® (Idebenone) in Duchenne Muscular Dystrophy

    Pratteln, Switzerland, May 27, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) for Puldysa® (idebenone) for the treatment of respiratory ...

  • GlobeNewswire

    Santhera Enters into License Agreement with Chiesi Group for Raxone® in LHON Valued at up to CHF 105 Million

    Pratteln, Switzerland, May 23, 2019 - Santhera Pharmaceuticals (SANN.SW) announces that it has entered into an exclusive license agreement with Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group), under which Chiesi Group will in-license Raxone® for the treatment of LHON for a total consideration of up to CHF 105 million (EUR 93 million), comprising an upfront cash payment of CHF 50 million (EUR 44 million) and near- to mid-term sales milestone payments of up to CHF 55 million (EUR 49 million). Chiesi Group is in-licensing the rights to Raxone in LHON and all other ophthalmological indications worldwide except the US and Canada, where Santhera retains rights.

  • GlobeNewswire

    Santhera Starts Collaboration in Gene Therapy Research for Congenital Muscular Dystrophy with the Biozentrum, University of Basel, Co-Financed by Innosuisse

    Pratteln, Switzerland, May 21, 2019 - Santhera Pharmaceuticals (SANN.SW) announces its collaboration with the Biozentrum of the University of Basel to advance gene therapy research for the treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2 MD or MDC1A). The program is supported by public funding for innovation in Switzerland through a grant from Innosuisse - the Suisse Innovation Agency. Innosuisse and Santhera will jointly invest CHF 1.2 million into this preclinical research collaboration.

  • GlobeNewswire

    Santhera Reports Strong Top-line Growth for 2018 and the Successful Expansion of its Rare Disease Pipeline

    Pratteln, Switzerland, April 29, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces the Group`s audited financial results for 2018. The Company reports a 38% increase in net revenues year-on-year to ...

  • GlobeNewswire

    Santhera to Present Long-term Efficacy Results with Idebenone in DMD at the 2019 MDA Clinical and Scientific Conference

    Pratteln, Switzerland, April 15, 2019 - Santhera Pharmaceuticals (SIX: SANN) and its collaborating clinical experts present results of long-term efficacy on respiratory function.

  • GlobeNewswire

    Santhera Raises up to CHF 22.1 Million by Placement of Shares and Credit Line

    Pratteln, Switzerland, April 4, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces that it has placed all of the remaining 500,000 registered shares from its existing authorized share capital in a private ...

  • GlobeNewswire

    Santhera Provides Update on Near-term Corporate Financing Initiatives

    Pratteln, Switzerland, April 3, 2019 - Santhera Pharmaceuticals (SANN.SW) announces that it has entered into a CHF 15.0 million credit line facility and is providing an update on ongoing corporate financing initiatives, including the issuance of equity and business development opportunities that would strengthen the financial base of the Company. Santhera has taken out a syndicated credit line which, subject to certain conditions, will provide up to CHF 15.0 million over a time period of nine months. Alongside this, Santhera is preparing for the issuance of up to 500,000 registered shares, representing 4.7% of its currently outstanding share capital.

  • GlobeNewswire

    Santhera Provides Update on Filing for Conditional Marketing Authorization in Europe for Puldysa® (Idebenone) in Duchenne Muscular Dystrophy

    Pratteln, Switzerland, March 28, 2019 - Santhera Pharmaceuticals (SANN.SW) announces its intention to file an application for Conditional Marketing Authorization (CMA) for Puldysa® (idebenone) for the treatment of respiratory dysfunction in Duchenne muscular dystrophy (DMD) with the European Medicines Agency (EMA). Following scientific advice from EU regulatory authorities, completion and filing of the CMA for Puldysa in DMD is planned for the second quarter of 2019. Santhera has expanded and substantiated its previous regulatory dossier with additional clinical data from patients treated with idebenone, new analyses of previously submitted data and new comprehensive natural history data, addressing requests from regulatory authorities.

  • GlobeNewswire

    Santhera's SYROS Study Shows Long-term Efficacy with Idebenone in Slowing Respiratory Function Loss in Patients with Duchenne Muscular Dystrophy

    Pratteln, Switzerland, February 25, 2019 - Santhera Pharmaceuticals (SIX: SANN) announces results from the SYROS study demonstrating that long-term treatment with idebenone consistently reduced the rate of respiratory function loss in patients with Duchenne muscular dystrophy (DMD) for up to 6 years in a real-world setting. This long-term data further supports the potential for idebenone to modify the course of respiratory function decline and delay the time to clinically relevant milestones. The SYROS study was a prospectively planned collection of long-term, retrospective real-world data from patients who completed the positive Phase III DELOS trial (18 out of 64) and were subsequently treated with idebenone (900 mg/day) for on average 4.2 years (range 2.4-6.1 years) under Expanded Access Programs (EAPs).

  • GlobeNewswire

    Santhera Raises Gross Proceeds of CHF 23.5 Million and Secures Acquisition of Option to Vamorolone Sub-license

    Pratteln, Switzerland, December 14, 2018 - Santhera Pharmaceuticals Holding AG (SANN.SW) has completed its ordinary capital increase with the placement of 3,133,334 new shares by way of an accelerated bookbuilding and raised gross proceeds of CHF 23.5 million. On December 12, 2018, Santhera Pharmaceuticals Holding AG announced the launch of an ordinary capital increase of up to 5,000,000 registered shares with a nominal value of CHF 1 each to be offered through an accelerated bookbuilding. After completion of the placement, a total of 3,133,334 shares were placed at CHF 7.50 per share.

  • GlobeNewswire

    Santhera Provides Update on the Share Placement

    Pratteln, Switzerland, December 14, 2018 - Santhera Pharmaceuticals Holding AG (SANN.SW) provides an update on the accelerated bookbuilding. On December 12, 2018, Santhera Pharmaceuticals Holding AG announced the launch of an ordinary capital increase of up to 5,000,000 registered shares with a nominal value of CHF 1 each to be offered through an accelerated bookbuilding. Based on the current status of the book, the share placement would amount to 3,133,334 new shares to be priced at CHF 7.50 per share, which would result in CHF 23.5 million gross proceeds.

  • GlobeNewswire

    Santhera Announces Financial Results for the First Nine Months of 2018

    Pratteln, Switzerland, December 12, 2018 - Santhera Pharmaceuticals (SIX: SANN) reports financial results for the nine months ended September 30, 2018, and confirms its guidance and positive outlook. Santhera ...

  • GlobeNewswire

    Santhera Launches Placement of Shares through Accelerated Bookbuilding

    Pratteln, Switzerland, December 12, 2018 - Santhera Pharmaceuticals Holding Ltd (SANN.SW) announces the launch of an ordinary capital increase of up to 5,000,000 registered shares with a nominal value of CHF 1 each to be offered through an accelerated bookbuilding. Following the resolution regarding the ordinary share capital increase adopted by the Extraordinary General Meeting held yesterday, Santhera launches the placement of up to 5,000,000 registered shares of the Company to be newly issued with a nominal value of CHF 1 each.